In this webinar, colleagues from Alcon will provide an overview of their external innovation funding and engagement opportunities for researchers across each of our King’s Health Partners working within the ophthalmology space.

The focus will be on the Alcon Seed Fund which aims to engage, identify and invest in early-stage*, disruptive innovation within the ophthalmology space.

Speakers:

• Barry Walsh CPhys MInstP, PMP, Senior Principal Engineer, R&D & Alcon Seed Fund, Alcon Ireland
• Luis Diaz Santana, LDSH Strategy

This will be followed by Q&A.

This webinar is open to all across King’s Health Partner organisations and will be of particular relevance to researchers in ophthalmology and their teams, as well as members of Tech Transfer teams.

(*early stage = Prototypes, pre-clinical data, First In Human clinical data.)

-

ABOUT ALCON

Alcon is a global leader in eye care, specializing in ophthalmic surgical and vision care products, with a focus on helping people see brilliantly.

With an over 75-year heritage, Alcon is the largest eye care device company in the world, with complementary businesses in Surgical and Vision Care. Alcon works in 60 countries and serve patients in more than 140 countries.

Alcon has a long history of industry firsts, and each year commits a substantial amount in Research and Development to meet customer needs and patient demands.

- 

ALCON SEED FUND

The Alcon Seed Fund (ASF) identifies and invests in early-stage, disruptive innovation within the ophthalmic field to accelerate the advancement of breakthrough solutions that address unmet clinical needs and improve patient outcomes globally. ASF complements Alcon's existing Alcon Research Institute (ARI) and Business Development and Licensing (BD&L) efforts by partnering with external organisations to fill portfolio gaps, enhance the development pipeline, and extend research opportunities.

Key Focus Areas

• Cataract: Advanced instrumentation, new IOL materials or designs with opportunity for enhanced performance
• Myopia: Device-based modalities with enhanced effectiveness vs. available treatment options
• Retina: Technologies or systems that can be used to visualize, diagnose or treat retinal diseases
• Ocular Health: Interventions that improve health status of the ocular surface
• Glaucoma: Medical Devices with step change improvement in risk-benefit for office-based or surgical interventions
• Contact Lenses: New optic and device technologies to drive incremental or breakthrough product performance in key indications, including myopia and presbyopia
• Digital Technologies: Improved visualization, analysis or modeling tools to support diagnosis, treatment planning and guided surgery; clinical decision support system
• White Space: Novel technologies with the potential to revolutionize the treatment of ophthalmic diseases

See: Innovative Eye Care Products & Solutions | Alcon